Efficient myoblast expansion for regenerative medicine use

Area of Science:

• Cellular Therapy
• Regenerative Medicine
• Biotechnology

Background:

• Autologous myoblast expansion is crucial for cellular therapies.
• Optimizing cell culture media is essential for maximizing therapeutic potential.
• Skeletal muscle cell growth medium-2 (SKGM-2) is a commercial standard.

Purpose of the Study:

• To compare the efficacy of a novel in-house medium (DFEFH) against commercial SKGM-2 for skeletal myoblast expansion.
• To evaluate the impact of different media on myoblast proliferation, differentiation, and fusion potential.

Main Methods:

• Skeletal myoblasts were cultured in either DFEFH (DMEM/F12 + growth factors) or SKGM-2.
• Cell proliferation, colony formation, CD56 expression, and gene expression (myostatin, myogenin) were analyzed across passages.
• Myotube formation and fusion potential were assessed to evaluate differentiation capacity.

Main Results:

• DFEFH medium resulted in >50% more colonies and significantly higher proliferation rates (3- to 9-fold increase) compared to SKGM-2.
• DFEFH culture led to a 87-fold greater cell yield by the 3rd passage, with higher CD56, lower myostatin, and higher myogenin expression.
• Myoblasts cultured in DFEFH exhibited superior fusion potential and formed myotubes with more nuclei, though fusion capacity decreased with passages.

Conclusions:

• The in-house DFEFH medium is superior to commercial SKGM-2 for expanding skeletal myoblasts.
• DFEFH promotes enhanced cell proliferation, improved morphology, and greater fusion potential, making it a promising option for cellular therapies.
• Optimized media formulations can significantly improve the yield and quality of myoblasts for therapeutic applications.